Cost-effectiveness of lurbinectedin with atezolizumab for extensive-stage small-cell lung cancer in the United States: impact of drug wastage reduction on economic outcomes.
Zhu J; Li Z; Song D; Liu W · 2026 · BMC health services research
WASTE classifies this as Methods Dead-End · AI classification, approximate
A method or design hit a limitation — check whether the same constraint applies to your setup.
Abstract (excerpt)
Background The IMforte trial had supported lurbinectedin as a recommended first-line maintenance therapy for patients with extensive-stage small-cell lung cancer (ES-SCLC), while its cost-effectiveness remains uncertain for patients and…
Excerpt shown for reference under fair use — read the full paper at the publisher.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Negative / Null Result ReportDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
Negative / Null Result ReportStenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis
Negative / Null Result ReportEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Replication FailureA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Negative / Null Result ReportSpironolactone for Heart Failure with Preserved Ejection Fraction
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: Europe PMC · DOI 10.1186/s12913-026-14653-5